Pulmonary vascular disease & thromboembolism
Relaxin Mimetic in Pulmonary Hypertension Associated with Left Heart Disease: Design and Rationale of Re-PHIRE
Study context
- Population
- Patients with pulmonary hypertension associated with left heart disease (PH-LHD) in the context of heart failure (HF)planned, to be randomized to four treatment groups
- Participants
- 220 patients
- Planned comparison
- AZD3427 versus placebo
- Primary endpoint
- Change in pulmonary vascular resistance
- Follow-up
- After 24 weeks of treatment
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Relaxin Mimetic in Pulmonary Hypertension Associated with Left Heart Disease: Design and Rationale of Re-PHIRE. ESC Heart Fail. Published 20 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →